Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tosufloxacin is a fluoroquinolone antibiotic used to treat a wide range of infections, including skin, respiratory, urinary, gynecological, ophthalmologic, otorhinologic (ear/nose/throat), and dental/oral surgical infections[1][4][7]. It acts as a bactericidal agent by inhibiting bacterial DNA gyrase and topoisomerase IV—enzymes essential for bacterial DNA replication and transcription[4][6]. Tosufloxacin is known for its broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria. However, it has a controversial safety profile compared to other fluoroquinolones due to associations with severe thrombocytopenia (low platelet count), nephritis (kidney inflammation), and hepatotoxicity (liver toxicity)[3][4]. The drug is marketed in Japan under the brand name Ozex[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tosufloxacin.